Application No.	Applicant(s)
09/828 217	HIRANO ET AL.
Examiner	Art Unit
ILIA OLISPENSKI	1644
GHTS. This application is subject and MPEP 1308. der 35 U.S.C. § 119(a)-(d) or (f). been received. been received in Application No cuments have been received in the cuments have been received in the cuments have been received in the cuments of this application. etted. Note the attached EXAMIN as reason(s) why the oath or decit be submitted.	e correspondence address application. If not included tion will be mailed in due course. THIS ct to withdrawal from issue at the initiative b. 08/624,650. his national stage application from the ply complying with the requirements ER'S AMENDMENT or NOTICE OF laration is deficient.
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached	
1) hereto or 2) to Paper No./Mail Date	
(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date	
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).	
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.	
6. ⊠ Interview Summa Paper No./Mail 8), 7. ⊠ Examiner's Ame	Date <u>1/3/06</u> .
	Examiner ILIA OUSPENSKI ars on the cover sheet with the (OR REMAINS) CLOSED in this or other appropriate communica GHTS. This application is subject and MPEP 1308. der 35 U.S.C. § 119(a)-(d) or (f). It been received. been received. been received in Application Not cuments have been received in the communication to file a received. It is subject to this application. atted. Note the attached EXAMIN is reason(s) why the oath or decide to be submitted. on's Patent Drawing Review (Property of BIOLOGICAL MATERIA (C)) should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written on the drawn header according to 37 CFR 1.1 (Sit of BIOLOGICAL MATERIA (C)) Should be written

Application/Control Number: 09/828,217 Page 2

Art Unit: 1644

DETAILED ACTION

1. Applicant's amendments/remarks, filed 11/18/2005, are acknowledged (and have been entered).

Claims 30 – 32 have been cancelled.

Claims 1 – 22 have been cancelled previously.

Claims 23, 27, and 29 have been amended.

Claims 23 – 29 are pending and being considered.

- 2. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the Issue Fee.
- 3. Authorization for this Examiner's Amendment was given in a telephone interview with Thomas M. Cunningham on 01/03/2006.

Examiner's Amendment

In the Specification:

4. In the TITLE: the phrase "METHOD OF IDENTIFYING CELLS EXPRESSING" has been replaced with -- AN ANTIBODY REACTIVE WITH --

Application/Control Number: 09/828,217 Page 3

Art Unit: 1644

In the Claims:

5. In claim 23, the phrase "An antibody" has been replaced with

-- An isolated antibody -- .

6. In claim 25, the word "monoclonal" has been deleted.

Reasons for Allowance

7. The following is an Examiner's Statement of Reasons for Allowance:

The Examiner's Amendment set forth supra, in conjunction with Applicant's amendment and arguments filed 11/18/2005, have obviated the previous rejection of record, mailed 05/18/2005.

Claims 23 - 29 are pending and allowed.

The prior art does not teach or suggest the claimed antibodies.

8. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ILIA OUSPENSKI whose telephone number is 571-272-2920. The examiner can normally be reached on Monday-Friday 9 - 5.

Art Unit: 1644

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ILIA OUSPENSKI

Patent Examiner

Art Unit 1644

January 3, 2006

PHILLIP GAMBEL, PH.D J.D.

PRIBARDY EVARABLE D.

PRIMARY EXAMINER
TOU COUTON (600